A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis

Inclusion Criteria:

1. A) Subject needing primary TKA due to degenerative joint disease (primary diagnosisof osteoarthritis), post-traumatic arthritis or inflammatory arthritis. OR B) Subject has undergone primary TKA with Smith+Nephew Porous knee system in past 12months to repair degenerative joint disease, post- traumatic arthritis orinflammatory arthritis and all the following conditions have been met:

• Preoperative KOOS JR and radiographs have been obtained

• 6-Month KOOS JR and radiographs have been obtained or these can be collectedprospectively in window per schedule of events

2. Subject agrees to consent and to follow the prospective study visit schedule (asdefined in the study protocol and informed consent form) by signing the IndependentReview Board (IRB)/Independent Ethics Committee (IEC) approved informed consentform.

3. Subject is willing to attend study follow-up visits for up to five (5) yearspost-surgery.

4. Subject is able to read, understand, and communicate responses to Patient ReportedOutcome assessments.

5. Subject is 18-80 years old (inclusive).

Exclusion Criteria:

1. Subject received TKA on the contralateral knee as a revision for a previously failedtotal or unicondylar knee arthroplasty.

2. Subject has a Body Mass Index (BMI) ≥ 40 at time of surgery.

3. Subject has ipsilateral hip arthritis resulting in flexion contracture.

4. At the time of enrolment, subject has one or more of the following arthroplastiesthat are not fully healed and well-functioning, as determined by the investigator:Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacingarthroplasty; Contralateral primary total knee or unicondylar knee arthroplasty.

5. Subject has a condition that may interfere with the TKA survival or outcome (e.g.Paget's or Charcot's disease, vascular insufficiency, lupus, muscular atrophy,uncontrolled diabetes, moderate to severe renal insufficiency or neuromusculardisease).

6. Subject has a known allergy to one or more of its components of the study device.

7. Any subject with hardware present in distal femur or proximal tibia.

8. Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55.

9. Subject is entered in another drug, biologic, or device study or has been treatedwith an investigational product in the past 30 days.

10. Subject, in the opinion of the Investigator, has an emotional or neurologicalcondition that would pre-empt their ability or willingness to participate in thestudy including mental illness, drug or alcohol abuse.

11. Subject is known to be at risk for lost to follow-up, or failure to return forscheduled visits.

12. Women who are pregnant, nursing, or of child-bearing potential who are not utilizinghighly effective birth control measures.

13. Subjects who have participated previously in this clinical trial and who have beenwithdrawn.